For patients with bladder cancer, invisible blood in urine may aid diagnosis
the ONA take:
According to new research published in the British Journal of General Practice, invisible blood in the urine may be able to be used to diagnose bladder cancer. Researchers at the University of Exeter Medical School in Exeter, United Kingdom, identified over 26,000 patients from the Clinical Practice Research Datalink and found that one in 60 patients over the age of 60 who had invisible blood in their urine were later diagnosed with bladder cancer.
The best known indicator of bladder cancer is visible blood in urine. Identifying invisible blood could boost early detection of bladder cancer, thereby improving outcomes compared with those who are diagnosed late.
According to the National Cancer Institute, if diagnosed with stage 1 bladder cancer, a patient has an 88% 5-year survival rate, but if diagnosed with stage 4 cancer, the 5-year survival rate drops to 15%.
The American Cancer Society says that nearly 75,000 Americans will be diagnosed with bladder cancer and about 16,000 will die from the disease in 2014. Bladder cancer is about three times more likely in men than women and occurs mainly in older adults.
Invisible blood in the urine may be able to be used to diagnose bladder cancer.
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians. Scientists at the University of Exeter Medical School found that one in 60 people over the age of 60 who had invisible blood in their urine (identified by their GP testing their urine) transpired to have bladder cancer.
The figure was around half those who had visible blood in their urine - the best known indicator of bladder cancer. However, it was still higher than figures for other potential symptoms of bladder cancer that warrant further investigation.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|